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Abstract
Multiple myeloma is the second commonest hematologic malignancy. It is characterized 
by neoplastic proliferation of a single clone of plasma cells in the bone marrow produc-
ing a monoclonal immunoglobulin and ultimately causing various complications and 
organ dysfunction. Over the last 10 years, management of multiple myeloma has dra-
matically changed due to the introduction of several novel therapies that have improved 
the disease outcome and prognosis, as well as the quality of life of patients with myeloma 
due to their safety, tolerability and efficacy. Additionally, the widespread utilization of 
autologous hematopoietic stem cell transplantation, which is still the standard of care 
for transplant-eligible patients, and the implementation of new therapeutic strategies 
such as drug combinations in addition to consolidation and maintenance therapies have 
resulted in further improvements in response rates and survival in patients with multiple 
myeloma. This book chapter will be an update on the novel therapies and the recent treat-
ment strategies in myeloma. The role of stem cell treatments in the era of novel therapies 
will be discussed thoroughly.
Keywords: multiple myeloma, hematopoietic stem cell transplantation, novel therapies, 
monoclonal antibodies
1. Introduction
Multiple myeloma (MM) is an incurable, debilitating and heterogeneous malignancy that has 
highly variable clinical course [1–6]. It is a plasma cell neoplasm characterized by neoplastic 
proliferation of a single clone of plasma cells in the bone marrow (BM) producing a monoclo-
nal immunoglobulin and causing anemia, renal failure, bone destruction and infectious com-
plications [7–9]. It is the second most commonly diagnosed hematologic malignancy (HM) 
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and it accounts for approximately 10% of all HMs [8]. The median age of MM at diagnosis is 
70 years in the United States of America (USA) and 72 years in Europe [9].
2. Diagnosis, staging, genetics and risk stratification
The diagnostic criteria for MM are: (1) clonal BM plasma cells ≥10% or biopsy-proven bony or 
extramedullary plasmacytoma and (2) at least one of the following: (a) evidence of end-organ 
damage such as anemia, lytic bone lesions, hypercalcemia and renal insufficiency, (b) clonal 
BM plasma cells ≥60%, (c) involved:uninvolved serum free light chain ratio ≥100 and (d) at 
least two focal lesions on magnetic resonance imaging [8, 10–15].
MM is usually classified into three stages: (1) stage I; all the following: serum albumin ≥3.5 g/
dL, serum beta 2 microglobulin (B2M) < 3.5 mg/L, normal serum lactic dehydrogenase (LDH) 
and no high-risk (HR) cytogenetics; (2) stage II: not fitting stages I and III with serum B2M: 
3.5–5.5 mg/L, and (3) stage III; all the following: serum B2M > 3.5 mg/L and HR cytogenetics 
or elevated serum LDH level [8, 13].
The following cytogenetic abnormalities have been reported in patients with MM: trisomies; 
monosomies; 17 p deletion; amp (1q20); t(14,16); t(14,20); t(4,14); t(6,14) and t(11,14) [8, 13, 16]. 
Also, the following molecular mutations have been reported in MM patients: NRAS, KRAS, 
TP53, BRAF, CCND1, FAM46C, MYC, XBP1, EZH2 and CHST15 [17–21]. Recently, the follow-
ing laboratory techniques have been utilized in the diagnosis and follow-up of patients with 
MM: (1) next-generation sequencing (NGS), (2) genomic and epigenetic studies, (3) micro-
RNA and (4) minimal residual disease (MRD) evaluation by flow cytometry, polymerase 
chain reaction, and NGS [17–22]. Mass accumulation rate will be used in the near future for 
susceptibility of human MM cell lines to standard-of-care therapies [23].
The HR features in MM include: (1) cytogenetic and molecular abnormalities that include: 
hypodiploid, 17 p deletion, t(4,14), t(14,16), t(14,20) and EZH2; (2) international scoring system 
stage II or III; (3) presence of comorbid medical conditions that limit therapy; (4) extramedul-
lary disease (EMD) and (5) renal failure, high serum LDH level and plasma cell leukemia [13, 
16, 21, 24, 25]. MM patients are stratified into three risk groups based on their cytogenetic 
profiles as follows: (1) HR that includes 17 p deletion, t(14,16) or t(14,20); (2) intermediate risk 
that includes: t(4,14) and amp (1q20)/gain (1q) and (3) standard risk that includes: trisomies, 
t(11,14) and t(6,14) [8, 13, 16]. Additional poor prognostic features include: age ≥60 years and 
refractory and/or relapsed MM (R/R-MM) [26].
3. New insights into the pathogenesis of MM
Despite the recent progress in understanding MM, the pathogenesis of the disease is incom-
pletely understood and is apparently multifactorial in nature [27]. The 10 hallmarks of cancer 
are: (1) self-sufficiency in growth signaling, (2) evasion of apoptosis, (3) insensitivity to anti-
growth mechanisms, (4) tissue invasion and metastases, (5) limitless replicative potential, (6) 
sustained angiogenesis, (7) avoidance of immune destruction, (8) reprogramming of energy 
metabolism, (9) tumor-promoting inflammation and (10) genome instability and mutation. 
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All the 10 hallmarks of cancer are present and active in MM and they contribute to tumor 
initiation, drug resistance, disease progression and relapse [28–30].
BM adipose tissue is a newly recognized contributor to MM oncogenesis and disease progres-
sion, particularly affecting MM cell metabolism, immune action and inflammation in addition 
to influencing angiogenesis [28]. BM adipose tissue may support MM through: (1) bioactive 
lipids such as fuel source, signaling molecule and substrate for lipid peroxidation and (2) 
MM supportive adipokines such as interleukin (IL)-6, tumor necrosis factor-α, MCP-1, PAI-1, 
resistin and leptin. The interaction between hypoxia, BM adipose tissue and angiogenesis is 
complicated [28].
The BM niche in patients with MM appears to play an important role in differentiation, migra-
tion, survival and drug resistance of malignant plasma cells [31, 32]. The BM niche is com-
posed of (1) cellular compartment that contains the following constituents: hematopoietic and 
nonhematopoietic cells, stromal cells, osteoblasts, osteoclasts, endothelial cells and immune 
cells and (2) noncellular compartment, which has the following constituents: extracellular 
matrix (ECM) and liquid milieu that has cytokines, chemokines and growth factors [31–34]. 
MM cells home to the BM, adhere to the ECM and BM stromal cells. Trafficking or homing 
ingress allows progression or metastasis of disease to new BM sites [31].
Bone destruction is the hallmark of MM and is mediated by osteoblasts [35]. Osteoblasts are 
the most important components of the MM microenvironment. They largely affect disease pro-
gression either directly or indirectly. Also, they may slow MM growth [36]. Normally, there is 
a balance between osteoblastic and osteoclastic activity and imbalance leads to development of 
disease lesions. Hence, increased osteoclastic activity is associated with MM [37]. Osteoclasts 
are the primary mediators of bone resorption in both healthy and pathological bone turnover. 
Bone anabolic agents hold potential for antimyeloma and antiosteolysis therapies [36].
MM pathophysiology is the result of the interaction between clonal plasma cells and the 
surrounding BM microenvironment [31, 32, 38–40]. BM angiogenesis represents a constant 
hallmark of MM progression partly driven by the release of proangiogenic cytokines from the 
tumor plasma cells, BM stromal cells and osteoclasts such as vascular endothelial growth fac-
tor (VEGF), basic fibroblast growth factor (bFGF) and metalloproteinases [31]. Also, BM stro-
mal cells from MM patients express several proangiogenic molecules such as VEGF, bFGF, 
angiopoietin-1, transforming growth factor-β, hepatocyte growth factor, platelet-derived 
growth factor and IL-1 [31]. The signaling pathways that are active in MM microenviron-
ment include Ras GAP, FAK, phosphoinositide 3-kinase (PI-3K)-akt, MEK-ERK and STAT 
[38]. Other signaling pathways that may also become new therapeutic targets in MM include 
RANKL, DKK1, sclerostin and activing-A [31, 39].
MicroRNAs play a crucial role in cancer progression [40]. They are the novel crossroads 
between MM cells and MM microenvironment [41]. Several microRNAs are dysregulated 
in MM [40]. Dysregulation of microRNAs in MM cells and MM microenvironment has 
important impacts on initiation of MM, disease progression and drug resistance [42, 43]. 
Approximately 95 microRNAs are expressed at high levels in MM, particularly miR-125b, 
miR-133a, miR-1 and miR-124a [40]. Deregulated microRNAs target genes regulating cell 
cycle, apoptosis, survival and cell growth [40]. Interactions between various constituents of 
BM microenvironment, particularly MM mesenchymal stem cells and MM cancer stem cells, 
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may be involved in disease initiation such as bone involvement, disease progression, relapse 
and drug resistance, so microRNAs may become very useful in designing targeted therapies 
in the field of precision medicine [27, 44–52]. Additionally, circulating microRNAs may serve 
as diagnostic and prognostic markers due to their impact on gene expression, biological func-
tion and survival, and microRNA-based assays may help in improving risk stratification in 
MM [27, 53–58].
4. Management of MM
Over the past two decades, management of MM has dramatically changed and this has trans-
lated into significant improvements in disease outcomes and prognosis. This unprecedented 
progress can be attributed to (1) the application of high-dose (HD) chemotherapy followed by 
autologous hematopoietic stem cell transplantation (HSCT), (2) improvement in supportive 
care strategies and (3) the introduction of several novel agents particularly immunomodula-
tory agents and proteasome inhibitors in the treatment of patients with MM [10, 13, 16, 59–61].
Cytotoxic agents that have been used in the treatment of MM include (1) corticosteroids such 
as dexamethasone and prednisolone, (2) conventional chemotherapies including melphalan, 
cyclophosphamide, liposomal doxorubicin, bendamustine, carmustine (BCNU), D-PACE 
(dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) and DCEP (dexa-
methasone, cyclophosphamide, etoposide, cisplatin) [62]. However, remarkable improve-
ments in survival of patients with MM have been achieved following the introduction of 
thalidomide, bortezomib and lenalidomide, as well as the recent introduction and approval 
of the following novel therapeutic agents: (1) newer proteasome inhibitors such as carfilzo-
mib and ixazomib; (2) histone deacetylase inhibitors such as panobinostat and vorinostat; (3) 
new immunomodulatory drugs such as pomalidomide; (4) monoclonal antibodies such as 
daratumumab and elotuzumab; (5) Bruton tyrosine kinase inhibitors such as ibrutinib; (6) 
IL-6 inhibitors such as siltuximab; (7) PI-3 K inhibitors and (8) various immunotherapeutic 
strategies including chimeric antigen receptor (CAR) T cells [10, 13, 15, 62–64].
5. Frontline and induction therapies in MM
Several studies have shown that VRD (bortezomib, lenalidomide, dexamethasone) regimen is 
well tolerated and highly effective in the treatment of newly diagnosed MM patients [65–70]. 
Once used as first-line therapy for MM, VRD has been shown to be superior to the doublet 
regimen of lenalidomide plus dexamethasone, as well as the triplet regimens VCD (bortezo-
mib, cyclophosphamide, dexamethasone) and VTD (bortezomib, thalidomide, dexametha-
sone) [68]. Carfilzomib, lenalidomide, dexamethasone (KRD) is an alternative promising 
regimen but has only been evaluated in small phase II studies in the frontline setting [68].
Response criteria in patients with MM subjected to various therapeutic regimens include 
MRD evaluation by multicolor flow cytometry or sequencing on bone marrow samples 
and imaging for EMD [59, 71]. MRD has recently been incorporated into the International 
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Myeloma Working Group response criteria and new studies have demonstrated that 
achievement of MRD negativity is a stronger predictor of survival than is traditional com-
plete response (CR) [72].
6. HSCT in patients with MM
6.1. Autologous HSCT
Autologous HSCT, performed at the time of initial diagnosis or at relapse, is considered the stan-
dard of care for patients with newly diagnosed MM who are younger than 70 years [8, 73, 74]. 
Even in the era of novel therapies, timing of performance of autologous HSCT, whether 
upfront or at relapse, is still controversial although there is global consensus strongly in favor 
of early autologous HSCT [75].
Autologous HSCT is not curative for MM [8, 73]. Allogeneic HSCT is the only curative therapy 
for MM but at the expense of increased treatment-related mortality (TRM), so candidates for 
allografts should be carefully selected from the pool of young patients with R/R-MM [76]. 
Several randomized clinical trials have shown that, compared with conventional chemother-
apy alone, HD chemotherapy followed by stem cell rescue is associated with prolonged event-
free survival (EFS) and overall survival (OS) [8, 73, 74]. The recent widespread implementation 
of autologous HSCT in conjunction with novel therapies has revolutionized the management 
of MM and has markedly altered the natural history of the disease by improving disease 
responses and response duration ultimately leading to significant improvement in OS [73].
Eligibility for autologous HSCT is determined by age, performance status, presence and 
severity of comorbid medical conditions, and frailty score as frailty has been shown to be a 
predictor of short survival and is considered an exclusion criterion for autologous HSCT [8].
6.2. Cryopreservation versus noncryopreservation of stem cells
For most types of transplants, cryopreservation of HSCs is necessary and is an essential com-
ponent of the clinical protocol [77]. Dimethyl sulfoxide (DMSO) is widely used as a cryo-
preservant for various types of stem cells and other body tissues. It has the following adverse 
effects: skin irritation, garlic breath or body odor; abdominal pain, nausea, vomiting and 
diarrhea; bronchospasm, chest tightness and dyspnea; altered heart rate and blood pressure, 
arrhythmias, heart block and myocardial ischemia; various degrees of organ dysfunction and 
death [77, 78]. Additionally, DMSO has in vitro toxicity in the form of induction of red blood 
cell hemolysis and reduction in platelet aggregation and activity [78].
Several studies and one meta-analysis have shown that noncryopreserved autologous HSCT 
for MM is simple, safe and cost-effective and gives results that are at least equivalent to autol-
ogous HSCT with cryopreservation [79–84]. TRM at day 100 post-HSCT has ranged between 
0.0 and 3.4% [80, 82–84]. Noncryopreserved stem cells can be infused till day 5 postapheresis 
without viability loss provided they are stored at +4°C in conventional blood bank refrigera-
tor [79, 81, 82, 84]. In a systematic review that included 16 studies having 560 patients with 
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various HMs including MM, hematopoietic engraftment was universal and only one graft 
failure was reported [79, 81]. The median times for engraftment following noncryopreserved 
autografts were 9–14 days for neutrophils and 14–25 days for platelets [79, 81]. Other recent 
studies on noncryopreserved autologous HSCT in patients with MM have shown the follow-
ing results: neutrophil engraftment between 10 and 14 days and platelet engraftment between 
13 and 25 days postautologous HSCT [85–92].
Melphalan is the standard chemotherapeutic agent that is used in the conditioning therapy 
prior to autologous HSCT in MM. The dose ranges between 140 and 200 mg/m2, given intrave-
nously (IV) [79, 81, 82, 93]. It is cleared from plasma and urine in 1 and 6 hours, respectively. 
Stem cells can be safely infused as early as 8–24 hours following melphalan administration 
[79, 81].
Recently, other drugs have been used in the conditioning therapy prior to autologous HSCT 
in MM either alone or in combination with HD melphalan [94–97]. Compared to HD melpha-
lan, the use of ixazomib, BCNU, bortezomib and IV busulfan either alone or in various combi-
nations with HD melphalan in the conditioning therapies has increased the overall response 
rates and the median OS without additional toxicity [93–97].
HSCT without cryopreservation has several advantages including (1) simplicity of implemen-
tation, (2) allowing autologous HSCT to be performed entirely as outpatient, (3) reduction 
of transplantation costs, (4) reducing the time between the last induction therapy and HD 
chemotherapy, (5) prevention of DMSO toxicity, (6) no significant loss of viability of the col-
lected HSCs provided stem cell infusion is made within 5 days of apheresis, (7) expansion of 
the number of medical institutions performing stem cell therapies and (8) potent engraftment 
syndrome and autologous graft versus host disease (GVHD) [79–84, 98, 99]. HSCT with-
out cryopreservation has the following disadvantages: (1) plenty of coordination is needed 
between various teams regarding timing of stem cell mobilization, apheresis, administra-
tion of conditioning therapy and infusion of stem cells; (2) limitation of the use of standard 
HD chemotherapy schedules such as BEAM (BCNU, etoposide, cytarabine and melphalan) 
employed in the autologous HSCT for lymphoma and (3) inability to store part of the collec-
tion and reserving it for a second autologous HSCT in case a rich product is obtained [79–84].
6.3. Outpatient HSCT
MM is the leading indication for autologous HSCT worldwide. Patients with MM are ideal 
candidates for outpatient autologous HSCT because of the following reasons: the ease of 
administering HD melphalan, the relatively low extra-hematological toxicity and the short 
period of neutropenia [85].
Outpatient autologous HSCT for MM is not yet established as a routine procedure, due to 
reluctance of certain centers and due to the absence of guidelines. However, reduction of 
costs and period of hospitalization are the driving forces behind the adoption of outpatient 
HSCT. The mixed inpatient/outpatient model has been shown to be highly feasible with very 
low rates of rehospitalization and TRM [100, 101].
Several studies have shown safety, feasibility and cost-effectiveness of outpatient autologous 
HSCT for MM [86–90]. Selection criteria for outpatient autologous HSCT include expected 
compliance, proximity to the HSCT center for daily visits, 24-hour caregiver support, favorable 
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performance status and favorable comorbidity profile [91]. Lack of caregiver is a limiting factor 
for outpatient autologous HSCT [92].
6.4. Tandem and second AHSCT
Even before the era of novel therapies, tandem autologous HSCT had been performed in 
patients with MM and the results of tandem transplants showed superior outcomes com-
pared to single autologous HSCTs [102, 103]. Later on, two single-center retrospective analy-
ses showed higher rates of progression-free survival (PFS) and OS in patients subjected to 
tandem autologous HSCT compared to recipients of single autologous HSCT [104, 105]. A 
meta-analysis that included six studies comparing tandem to single autologous HSCT in 
patients with MM showed: (1) no difference between the two forms of autologous HSCT 
with respect to OS and EFS and (2) tandem autologous HSCT was associated with improved 
response rates but at the expense of increased TRM [106]. However, this meta-analysis was 
criticized as it included a study with significant statistical errors [107].
Several studies have shown that a second autologous HSCT used as part of salvage therapy 
in patients with MM relapsing after the first autologous HSCT has been found to be safe and 
feasible particularly in carefully selected patients [108–112]. Factors associated with the suc-
cess of second autologous HSCT include younger age, B2M < 2.5 mg/L at diagnosis, remission 
duration >9 months from first autologous HSCT, > partial response achieved in response to 
the first autologous HSCT and performance of second autologous HSCT before relapse and 
within 6–12 months from the first autologous HSCT [113, 114].
6.5. Allogeneic HSCT in MM
Although allogeneic HSCT represents the only potentially curative therapeutic modality in 
patients with MM, it is associated with relatively high TRM [76, 115, 116]. The advent of reduced 
intensity conditioning (RIC) and the application of autologous-allogeneic tandem HSCT 
approaches have broadened the use of allogeneic HSCT in patients with MM. Autologous-
allogeneic tandem HSCT may overcome the negative impact of 17 p deletion and/or t(4,14) 
and the achievement of molecular remission in patients having HR cytogenetics has resulted 
in long-term freedom from disease [117].
In patients with HR disease or those relapsing after autologous HSCT, particularly younger 
patients who are fit for allografts, salvage therapy with novel agents followed by RIC alloge-
neic HSCT has been shown to provide significant PFS benefit [76, 118–121]. In patients lacking 
human leukocyte antigen (HLA)-matching sibling donors, alternate donors such as matched 
unrelated donors, cord blood transplantation and haploidentical forms of allogeneic HSCT 
have been employed and they have shown feasibility and effectiveness [115, 122–124].
7. Consolidation and maintenance therapies in MM
Almost all patients with MM relapse after autologous HSCT. Hence, treatment given in the 
postautologous HSCT period is aimed at suppression of residual disease in order to prolong 
duration of response, OS and PFS while minimizing toxicity [125, 126].
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The use of novel therapies in the consolidation phase following single or tandem autologous 
HSCT has been shown to enhance the rate as well as the quality of response thus contributing 
to improvements in clinical outcomes including prolongation of PFS [126]. Bortezomib-based 
regimens used as consolidation therapy after autologous HSCT in patients with MM have 
been shown to be effective in the improving PFS and decreasing relapse rate [127].
Maintenance therapy represents an important therapeutic strategy to delay disease progres-
sion and relapse [125, 126]. The following drugs have been used in postautologous HSCT 
maintenance: interferon, thalidomide, bortezomib and carfilzomib [125, 126, 128–130]. 
Bortezomib is safe, well tolerated and efficacious and it can be used with no risk of second 
malignancy till disease progression, but its disadvantages include cost and effects on quality 
of life (QoL) [126, 130].
In February 2017, the Food and Drug Administration in the USA approved the use of 
lenalidomide as maintenance therapy after autologous HSCT for patients with MM, after 
showing efficacy and safety in several studies [131]. Lenalidomide has tumoricidal and 
immunomodulatory activities against MM [132]. Several studies have shown the efficacy 
of lenalidomide maintenance after autologous HSCT as this therapy has been shown to be 
associated with significant improvements in OS, PFS and longer time to disease progression 
[133–136]. A multicenter, randomized double-blind study that included 306 patients with 
newly diagnosed MM ≥65 years of age and ineligible for autologous HSCT treated initially 
with melphalan, prednisolone and lenalidomide induction followed by lenalidomide versus 
placebo maintenance showed the following results: (1) significant prolongation of PFS, (2) 
maximum benefit was achieved in patients 65–75 years of age and (3) 3-year second primary 
tumor of 7% in the lenalidomide arm versus 3% in the placebo arm [132]. Other studies 
on lenalidomide maintenance have shown more toxicity and low rate of development of 
second tumors [133, 134]. Lenalidomide maintenance can be initiated as early as day 100 
postautologous HSCT [133]. Duration of lenalidomide maintenance longer than 3 years has 
been associated with further improvement in survival [134]. Several studies performed in 
patients with newly diagnosed MM subjected to autologous HSCT have shown continuous 
therapy to be more effective in prolongation of OS and PFS that limited the duration of 
treatment [137–141].
8. Novel therapies in MM
The novel therapies that have recently been introduced into the treatment of MM include (1) 
proteasome inhibitors such as bortezomib, carfilzomib and ixazomib; (2) immunomodulatory 
agents such as thalidomide, lenalidomide and pomalidomide; (3) monoclonal antibodies such 
as daratumumab and elotuzumab and (4) histone deacetylase inhibitors such as panobinostat, 
in addition to other classes of medications that can also be used in the treatment of MM such 
as glucocorticoids, DNA alkylating agents, as well as doxorubicin, cisplatinum and etoposide 
[10, 13, 15, 62–64]. Novel agents and targeted therapies that are either currently used or under 
development for the treatment of MM are shown in Table 1 [61, 62, 142–150].
Several cell cycle regulatory proteins have been proposed as therapeutic targets in patients 
with MM. Other targets that have already been identified in MM include microtubules, 
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kinesin motor proteins, aurora kinases, polo-like kinases and the anaphase-promoting 
complex/cyclosome [151]. The novel therapies that are used in the treatment of MM differ 
in their modes of action. Nevertheless, each drug has its own side effects that should be 
considered particularly once treating patients with comorbid medical conditions and once 
these novel agents are used in combination with other drugs [152].
8.1. Daratumumab
Daratumumab is a human IgG
k
 monoclonal antibody that targets CD38, which is a cell surface 
protein that is overexpressed in MM cells. It is given IV at a dose of 16 mg/kg weekly [153–156]. 
It induces death of MM cells by several mechanisms including (1) complement-dependent 
cytotoxicity, (2) antibody-dependent cell-mediated cytotoxicity, (3)  antibody-dependent 
 cellular phagocytosis and (4) apoptosis [153–156].
Daratumumab has shown substantial efficacy as monotherapy in heavily pretreated patients 
with MM as well as in combination with bortezomib in patients with newly diagnosed MM 
[154]. Two phase III randomized clinical trials in R/R MM using daratumumab in combina-
tion with either bortezomib and dexamethasone or lenalidomide and dexamethasone showed 
1. Monoclonal antibodies: Anti-CD 38 (daratumumab, elotuzumab, isatuximab, MOR202), anti-CD138 (indatux-
imab ravtansine), anti-interleukin-6 (siltuximab), anti-RANKL (denosumab), anti-KIR2DL1/2/4 (IPH2101)
2. Immunomodulatory agents: thalidomide, lenalidomide, pomalidomide
3. Proteasome inhibitors: bortezomib, carfilzomib, ixazomib
4. Histone deacetylase inhibitors: panobinostat, vorinostat, romidepsin, ricolinostat
5. mTOR inhibitors: everolimus, temsirolimus
6. Checkpoint (programmed cell death protein 1) inhibitors: nivolumab, pembrolizumab
7. Bruton’s tyrosine kinase inhibitors: ibrutinib
8. BCL2 antagonists (BH3 mimetics): venetoclax, obatoclax, navitoclax
9. Cyclin-dependent kinase inhibitors: dinaciclib
10. MEK inhibitors: selumetinib
11. Kinesin spindle protein 1 inhibitors: filanesib, array 520
12. Selective inhibitors of nuclear transport: selinexor
13. Phosphoinositide 3-kinase-Akt inhibitors: perifosine, afuresertib
14. PIM kinase inhibitors: LGH 447
15. Vaccines: PVH-410
16. Chimeric antigen receptor T cells (CAR T cells): directed against:
a. CD-19
b. CD-38
c. B-cell maturation antigen
d. Cell surface glycoprotein
Table 1. Novel agents and targeted therapies that are either currently used or under development for the treatment of 
multiple myeloma.
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significantly longer PFS with manageable toxicity [154, 156]. In a phase III randomized clinical 
trial performed in patients with newly diagnosed MM, not eligible for autologous HSCT, the 
addition of daratumumab to bortezomib, melphalan and prednisolone decreased the risk of 
death and disease progression but was also associated with higher rates of infections [155]. The 
adverse effects of daratumumab include infusion-related reactions, hematologic toxicity in the 
form of neutropenia and thrombocytopenia and various infectious complications [153–156].
8.2. Elotuzumab
Elotuzumab is an immunostimulatory monoclonal antibody targeting signaling lymphocyte 
activation molecule F7 (SLAMF7) [157]. While no responses to elotuzumab as a single agent 
were obtained, the addition of elotuzumab to lenalidomide and dexamethasone in RR-MM 
patients resulted in overall response rate (ORR) of 79% compared to 66% ORR obtained with 
lenalidomide and dexamethasone alone [142, 158]. Also, in a phase III randomized clinical 
trial in patients with R/R-MM, the combination of elotuzumab, lenalidomide and dexametha-
sone decreased the risks of death and disease progression by 30% [157].
8.3. Pomalidomide
Pomalidomide is a third-generation immunomodulatory agent that has been approved 
for patients with progressive MM or those who have received at least two lines of therapy 
[159]. It has been shown to be effective in combination with dexamethasone ± carfilzomib 
or other agents in patients with R/R-MM or in those with HR cytogenetics [159–162]. The 
use of pomalidomide combined with low-dose dexamethasone in heavily pretreated patients 
with R/R-MM has been shown to be cost-effective as the combination has produced clinical 
outcomes comparable to those obtained by daratumumab alone or carfilzomib alone [5].
8.4. Carfilzomib
Carfilzomib is a second-generation proteasome inhibitor [163]. It is well tolerated and causes 
minimal neurotoxicity. It has demonstrated promising activity in patients with MM who are 
refractory to bortezomib or immunomodulatory agents [163–165]. It can be combined with 
dexamethasone or other novel agents [164–166].
It is able to sensitize 24% of bortezomib-refractory MM patients. When combined with dexa-
methasone in R/R-MM, it resulted in superior outcome in terms of ORR and PFS compared 
to bortezomib and dexamethasone combination [158]. Also, it is under evaluation for patients 
with newly diagnosed MM [166].
8.5. Panobinostat
Histone deacetylase inhibitors such as panobinostat and vorinostat have demonstrated some 
activity against MM and they have multiple proposed mechanisms of actions once used in 
the treatment of MM [167]. Panobinostat is a potent oral pan-deacetylase inhibitor. It affects 
growth and survival of MM cells through alteration of (1) gene expression through epigenetic 
modification and (2) protein metabolism by inhibiting protein degradation [168–171]. The 
approval of panobinostat for the treatment of MM was based on the results of phase III ran-
domized double-blind clinical trial (PANORAMA 1), which demonstrated improvement in 
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median PFS of 7.8 months for panobinostat, bortezomib and dexamethasone in comparison 
with placebo, bortezomib and dexamethasone [168–171]. Panobinostat, in combination with 
bortezomib and dexamethasone, was recently approved in the USA, Europe and Japan for the 
treatment of patients with MM who had failed at least two prior regimens including bortezo-
mib and an immunomodulatory agent [168–171]. A meta-analysis that included 11 clinical tri-
als and 700 patients with R/R-MM treated with panobinostat demonstrated not only efficacy 
but also safety of panobinostat in combination with other agents [172]. The main toxic effects 
of panobinostat are thrombocytopenia and diarrhea. However, several studies showed other 
adverse effects including lymphopenia, neutropenia and anemia, nausea, vomiting, consti-
pation and abdominal pain, asthenia, fatigue, peripheral edema and peripheral neuropathy 
[167–172]. Ongoing clinical trials are evaluating the role of panobinostat in combination with 
drugs other than bortezomib in R/R-MM, in combination with various drugs in newly diag-
nosed disease and in maintenance therapy of myeloma [169].
8.6. CAR T cells
CAR is a hybrid antigen receptor that is composed of an extracellular antigen-binding domain 
and an intracellular signaling domain. T cells genetically targeted with a CAR to B-cell malig-
nancies have demonstrated tremendous clinical outcome [173]. Immunotherapy using CAR-
mediated T cells has demonstrated high response rates in patients with B-cell malignancies. 
CAR T-cell therapy is a cellular therapy that redirects a patient’s T cells to specifically target 
and destroy tumor cells [174]. CARs are genetically engineered fusion proteins composed of 
antigen recognition domain derived from a monoclonal antibody as well as an intracellular 
T-cell signaling domain and a costimulatory domain [174].
There are multiple steps in the production of CAR T cells and these include (1) leukapheresis 
to separate leukocytes; (2) enrichment of leukapheresis product with T cells; (3) separation of 
T-cell subsets at the level of CD4/CD8 composition using specific antibody-based conjugates 
or markers; (4) T-cell selection or activation, gene transfer or genetic modification and viral 
transduction; (5) volume expansion of T cells, isolation, washing and culture followed by 
cryopreservation and (6) infusion of CAR T cells [174, 175].
Adverse effects of CAR T-cell therapy include cytokine release syndrome (CRS), neurotoxic-
ity, on target/off tumor recognition and anaphylaxis. Additionally, theoretical toxicities of 
CAR T cells include clonal expansion secondary to insertional oncogenesis, GVHD and off-
target antigen recognition [176]. Management of CAR T-cell toxicity includes supportive mea-
sures, immunosuppression with tocilizumab (IL-6) receptor blockade for CRS and suicide or 
elimination genes to allow for selective depletion of CAR T cells [176].
CAR expressing T cells have demonstrated success in the treatment of B-cell lymphoid malig-
nancies particularly CD19+ acute lymphoblastic leukemia and chronic lymphocytic leukemia 
[177]. Cell surface glycoprotein (CS1) is highly expressed on MM cells and is an ideal target 
for the treatment of MM, that is, CS1 can be targeted by CAR natural killer cells to treat 
MM [177]. A patient with advanced and refractory MM received myeloablative treatment 
with melphalan 140 mg/m2, followed by autologous HSCT, and then infusion of CTL019 
CAR resulted in CR with no disease progression for 12 months after CAR T-cell infusion 
[178]. CAR T cells can target the following antigens in patients with MM: B-cell maturation 
 antigen (BCMA), CD138, CD19 and kappa-light chain [179]. A bispecific T-cell engager (BiTE) 
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targeting BCMA and CD3E (BI 836909) has been developed and it has been shown to be highly potent and efficacious to selectively deplete BCMA-positive MM cells; thus, it represents a 
novel immunotherapeutic approach in the treatment of MM [180]. CARs are proteins that 
incorporate antigen domain, costimulatory domains and T-cell activation domains [181]. 
Only a limited number of patients with MM received CAR T-cell therapy, but preliminary 
results are encouraging [179].
BCMA is only expressed on some B cells, normal plasma cells and malignant plasma cells. 
The first clinical trial using CAR T cells targeting BCMA that is expressed in most cases of 
MM included 12 patients [181]. After dose escalation in the infusion of CAR-BCMA cells was 
used, the trial showed remarkable success and impressive activity against MM cells as BM 
plasma cells became undetectable by flow cytometry and patients entered stringent CR last-
ing for 17 weeks before relapse [181]. Another clinical trial using CAR-BCMA that included 21 
patients showed increase in response rate from 89 to 100% after dose escalation [182].
9. Refractory and/or relapsed MM (R/R-MM)
The course of MM progression is highly variable as almost all patients with MM who respond 
to initial therapy will eventually relapse and require further treatment [6]. The introduction 
of novel agents over the last 15 years, the implementation of new therapeutic strategies and 
the adoption of drug combinations that include highly effective and tolerable drugs have 
improved (1) the clinical outcome dramatically as response rates have increased from approx-
imately 30% with single agents to about 90% with combination therapies and (2) the QoL even 
in heavily pretreated patients. However, determining the optimal sequence and combination 
as well as timing of each agent is necessary [6]. In a retrospective analysis of 628 patients 
with newly diagnosed MM who developed relapse after initial therapy, it was found that 
prolonged duration of treatment was associated with improved survival [141]. Unfortunately, 
secondary plasma cell leukemia and EMD still present difficult therapeutic challenges [16].
There is no standard of care for MM relapse after autologous HSCT [183, 184]. Regimens that 
are composed of combination therapy with (1) drugs having synergistic effect and no cross-
resistance and (2) one or two novel therapies are generally preferred as they lead to deeper and 
longer responses that are translated into improved survival [16, 183–185]. However, treatment 
should be individualized based on toxicity as well as patient and disease characteristics [184]. 
A meta-analysis of phase III randomized controlled trials showed that, compared to doublet 
regimens, triplets resulted in improved OS, PFS, very good partial response and CR although 
the risk of having grade III/IV drug adverse effects was higher with triplet regimens [185].
Mechanisms of drug resistance in MM include (1) multidrug-resistant gene polymorphism, 
(2) P-glycoprotein overexpression in MM cells, (3) microenvironmental changes, (4) clonal 
evolution including, (5) cancer stem cells, (6) upregulation and downregulation of various 
micro-RNAs and (7) selected CD34+, CD 138+, B7-, H1+, CD19- plasma cell accumulation after 
treatment [40].
Therapeutic options for patients with R/R-MM include (1) salvage therapy; combination of old 
and new therapies such as (a) bortezomib, thalidomide, cisplatin, cyclophosphamide, etopo-
side and doxorubicin (VTD-PACE); (b) KRD/carfilzomib, pomalidomide and dexamethasone 
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(KPD) ± PACE or (c) daratumumab-based therapy; (2) second autologous HSCT; (3) alloge-
neic HSCT in carefully selected patients and (4) enrollment in clinical trials [8, 11, 13, 16]. 
Specific agents that are used in the treatment of R/R-MM include (1) immunomodulatory 
agents such as thalidomide, lenalidomide and pomalidomide; (2) proteasome inhibitors such 
as bortezomib, carfilzomib and ixazomib; (3) monoclonal antibodies such as daratumumab 
and elotuzumab; (4) histone deacetylase inhibitors such as panobinostat and (5) pembroli-
zumab [6, 142, 157, 158, 164, 186]. The use of pembrolizumab (antiprogrammed cell death 1) 
in combination with lenalidomide and dexamethasone in patients with R/R-MM resulted in 
76% ORR [142, 158].
10. Management of MM patients having renal failure
Renal impairment (RI) is one of the most common complications of MM as 20–50% of patients 
with newly diagnosed MM present with RI, while 40–50% of patients develop RI during the 
course of the disease and about 5% of myeloma patients have dialysis-dependent renal failure 
(RF) at presentation [187–191]. In patients with MM, the causes of RI include myeloma cast 
nephropathy, excess of monoclonal free light chains causing proximal renal tubular damage, 
dehydration, infectious complications, hypercalcemia, hyperuricemia, use of nephrotoxic 
drugs and contrast media, hyperviscosity, myeloma cell infiltration and amyloid deposition 
[187–189, 192].
Bortezomib, thalidomide, lenalidomide and dexamethasone in various combinations can be 
used in the treatment of MM patients having RF and their use has been associated with high 
response rates and recovery of even partial or complete recovery of renal function [187–189, 
191, 192]. In early chemotherapy trials, RF was considered a predictor of poor prognosis, 
patients with hemodialysis were reported to have a poorer prognosis and RF was considered 
an exclusion criterion from autologous HSCT because of the concerns about higher rates of 
treatment-related toxicity and nonrelapse mortality (NRM) due to mucositis, infectious com-
plications and encephalopathy [187, 190]. However, recent studies have shown that autolo-
gous HSCT in patients with MM and RF has been associated with partial or complete recovery 
of renal function even in dialysis-dependent patients [190]. Therefore, autologous HSCT can 
be offered to patients with MM and RF with acceptable toxicity and NRM and a significant 
improvement in renal function that may be encountered in approximately one third of patients 
[187, 190]. In patients with MM and RF, a melphalan dose of 200 mg/m2 can be administered in 
the conditioning therapy of auto-HSCT without an increase in toxicity and NRM [190].
Kidney transplantation is the treatment of choice for most patients with end-stage renal fail-
ure (ESRD) as it is associated with improved survival and QoL compared to hemodialysis 
[193]. Even in patients with MM having RF, kidney transplantation is a valid therapeutic 
option in well-selected patients who achieve control of their disease and maintain a durable 
remission preferably for 3–5 years and have stable light chain levels but this option should 
be considered early in the course of the disease [194–197]. Combined HSCT, predominantly 
autologous HSCT, and renal transplantation have been performed for patients having various 
hematological disorders such as plasma cell dyscrasias [198–202]. Patients with MM having 
ESRD, either on regular hemodialysis or not, can be offered not only HSCT but also combined 
HSCT and renal transplantation either simultaneously or sequentially [198, 199, 203–206].
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11. Conclusions and future directions
The introduction of several novel agents and targeted therapies over the last 10 years has 
revolutionized the management of MM and has produced unprecedented outcomes in terms 
of disease control and OS. Currently, novel agents and targeted therapies are used in the fol-
lowing settings: (1) prior to HSCT to reduce tumor burden and to optimally control MM, (2) 
following HSCT as consolidation and maintenance therapy to allow long-term disease control 
and (3) as salvage therapy in case of relapse of MM after HSCT.
However, novel agents and targeted therapies should not be considered as a form of replace-
ment to HSCT, but instead these two valuable therapeutic interventions should be considered 
complementary to each other. The smart combination of novel agents and targeted therapies 
with various forms of HSCT in the new treatment paradigm of MM will ultimately lead to 
higher cure rates and longer disease controls.
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